Breast Cancer PSMA PET
Eligible age
18–90 yrs
Accepts
Women
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET/CT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSMA-avid; and thus PSMA-based radionuclide therapy can be a valid treatment option for TNBC, and clinical trials can be designed for this purpose. Thirty metastatic TNBC patients will be enrolled and will be on the study for maximum of 4 weeks.
Sponsor: Ahmad Shariftabrizi
You may qualify if…
- ✓ Female \>= 18 years of age
- ✓ Patients in distantly metastatic TNBC based on the initial diagnosis biopsy.
- ✓ Patient should have FDG positive metastatic lesions on the initial PET/CT scan performed in this study to be further included.
You may not qualify if…
- ✕ Patients with known active other malignancy.
- ✕ Unable to tolerate PET/CT procedure.
- ✕ Pregnant or breastfeeding.
- ✕ Patients with any medical condition that might compromise the safety of subject during PET acquisitions.
Where it's recruiting
Iowa City
Source: ClinicalTrials.gov · NCT06586047 · last updated 2026-08-06